CYTK: MYQORZO is set for broader HCM approval as commercial and pipeline strategies accelerate
ACACIA-HCM data has positioned MYQORZO for potential regulatory expansion to all HCM patients, with strong commercial momentum in OHCM and preparations for NHCM. The company is also advancing omecamtiv mecarbil in advanced heart failure, with a confirmatory trial designed to optimize outcomes.Based…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.